Exchange Traded Concepts LLC Buys 3,103 Shares of Thermo Fisher Scientific Inc. $TMO

Exchange Traded Concepts LLC boosted its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 109.6% in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 5,934 shares of the medical research company’s stock after buying an additional 3,103 shares during the period. Exchange Traded Concepts LLC’s holdings in Thermo Fisher Scientific were worth $2,878,000 at the end of the most recent reporting period.

Other institutional investors have also recently modified their holdings of the company. Matrix Asset Advisors Inc. NY boosted its stake in Thermo Fisher Scientific by 0.6% in the 3rd quarter. Matrix Asset Advisors Inc. NY now owns 21,511 shares of the medical research company’s stock worth $10,433,000 after purchasing an additional 134 shares in the last quarter. Cohen Investment Advisors LLC lifted its stake in shares of Thermo Fisher Scientific by 5.3% in the third quarter. Cohen Investment Advisors LLC now owns 7,005 shares of the medical research company’s stock worth $3,398,000 after buying an additional 355 shares in the last quarter. Perennial Advisors LLC grew its holdings in shares of Thermo Fisher Scientific by 0.8% during the third quarter. Perennial Advisors LLC now owns 16,111 shares of the medical research company’s stock valued at $7,814,000 after buying an additional 132 shares during the last quarter. Brighton Jones LLC raised its holdings in Thermo Fisher Scientific by 1.8% in the 3rd quarter. Brighton Jones LLC now owns 5,063 shares of the medical research company’s stock worth $2,456,000 after acquiring an additional 88 shares during the last quarter. Finally, Evanson Asset Management LLC bought a new position in Thermo Fisher Scientific in the 3rd quarter valued at approximately $218,000. 89.23% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several research analysts have recently weighed in on TMO shares. Royal Bank Of Canada set a $561.00 price target on Thermo Fisher Scientific and gave the stock an “outperform” rating in a research note on Tuesday, September 2nd. Weiss Ratings reissued a “hold (c)” rating on shares of Thermo Fisher Scientific in a report on Tuesday, October 14th. Argus lifted their price objective on Thermo Fisher Scientific from $580.00 to $610.00 and gave the stock a “buy” rating in a report on Wednesday, October 29th. Cowen reissued a “buy” rating on shares of Thermo Fisher Scientific in a report on Thursday, October 23rd. Finally, Wells Fargo & Company boosted their price target on Thermo Fisher Scientific from $635.00 to $675.00 and gave the company an “overweight” rating in a research note on Monday, December 15th. One equities research analyst has rated the stock with a Strong Buy rating, twenty have assigned a Buy rating and three have issued a Hold rating to the stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $616.60.

Thermo Fisher Scientific Stock Up 0.3%

NYSE TMO opened at $581.50 on Friday. The stock’s 50-day moving average price is $573.11 and its 200-day moving average price is $501.69. The company has a market capitalization of $218.48 billion, a P/E ratio of 33.59, a price-to-earnings-growth ratio of 4.11 and a beta of 0.90. The company has a quick ratio of 1.11, a current ratio of 1.50 and a debt-to-equity ratio of 0.62. Thermo Fisher Scientific Inc. has a 52 week low of $385.46 and a 52 week high of $610.97.

Thermo Fisher Scientific (NYSE:TMO) last issued its quarterly earnings results on Wednesday, October 22nd. The medical research company reported $5.79 earnings per share for the quarter, beating the consensus estimate of $5.50 by $0.29. The business had revenue of $11.12 billion for the quarter, compared to the consensus estimate of $10.90 billion. Thermo Fisher Scientific had a net margin of 15.02% and a return on equity of 16.97%. The company’s revenue for the quarter was up 4.9% on a year-over-year basis. During the same quarter in the previous year, the firm earned $5.28 earnings per share. Thermo Fisher Scientific has set its FY 2025 guidance at 22.600-22.860 EPS. On average, equities research analysts predict that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current year.

Thermo Fisher Scientific Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Thursday, January 15th. Shareholders of record on Monday, December 15th will be paid a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a yield of 0.3%. The ex-dividend date is Monday, December 15th. Thermo Fisher Scientific’s dividend payout ratio is presently 9.94%.

Thermo Fisher Scientific declared that its board has approved a stock repurchase plan on Thursday, November 6th that authorizes the company to buyback $5.00 billion in shares. This buyback authorization authorizes the medical research company to reacquire up to 2.4% of its shares through open market purchases. Shares buyback plans are generally a sign that the company’s leadership believes its shares are undervalued.

Insiders Place Their Bets

In other news, VP Lisa P. Britt sold 10,225 shares of the company’s stock in a transaction dated Friday, November 7th. The stock was sold at an average price of $571.62, for a total value of $5,844,814.50. Following the completion of the transaction, the vice president owned 14,145 shares of the company’s stock, valued at $8,085,564.90. This represents a 41.96% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, EVP Michael D. Shafer sold 10,725 shares of Thermo Fisher Scientific stock in a transaction that occurred on Tuesday, November 25th. The shares were sold at an average price of $600.00, for a total value of $6,435,000.00. Following the sale, the executive vice president directly owned 18,731 shares in the company, valued at $11,238,600. This trade represents a 36.41% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders sold 149,271 shares of company stock valued at $86,507,282. Insiders own 0.33% of the company’s stock.

About Thermo Fisher Scientific

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.